ClinicalTrials.gg

Program

ASC35

A development code. Also written as “ASC35 Injection B, for subcutaneous use”.

Its studies are led by Ascletis Pharma.

Furthest: phase 1, since Sep 21, 20261 company-led study, 1 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascletis Pharma11 open or runningphase 1since Sep 21, 2026Sep 21, 2026Jun 2027phase 1 · NCT07842640

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2026First study: phase 1 study in Chronic Weight ManagementFirst studyNCT07842640 · 84 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 1 study in Chronic Weight ManagementNCT07842640

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07842640Chronic Weight Management · United States1RecruitingJun 202784

How it is read

Names in the registry

  • “ASC35 Injection B, for subcutaneous use”, 1 entry

Codes read as this program: ASC35.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.